Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GS1-144 in Healthy Chinese Participants
NCT06385158Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in vasomotor symptoms comparing GS1-144 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events at Day 4. Started Jan 2024; status: completed.
02
Drugs
GS1-144
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06385158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385158.